Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bayer/J&J contemplate edge of the earth in VTE as MAGELLAN scuppers Xarelto

This article was originally published in Scrip

Executive Summary

Bayer and Johnson & Johnson's attempts the circumnavigate the world of venous thromboembolism (VTE) prevention with their oral Factor Xa inhibitor Xarelto (rivaroxaban) have hit an unexpected setback in the MAGELLAN study of medically ill patients.

You may also be interested in...



J&J Sees A Path Forward For Xarelto In Post-Hospital VTE Despite MARINER Failure

The company says the MARINER data combined with prior MAGELLAN results in acute medically ill patients support prophylaxis for VTE following a hospital stay in select individuals. However, there is no regulatory path forward in heart failure based on the COMMANDER HF study.

Another Failure For Biohaven’s Troriluzole

Biohaven’s investigational glutamate modulator troriluzole did not improve symptoms in patients with mild-to-moderate disease, adding to the list of failures in Alzheimer’s disease, as well as for the product itself.

FDA Approval Opens Up Gastric Cancer To Daiichi Sankyo/AZ’s Enhertu

The two companies can now market their HER-2 targeting antibody-drug conjugate in its second tumor type as they look to expand beyond breast cancer.

Topics

Related Companies

UsernamePublicRestriction

Register

OM013164

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel